BUND FINANCE

BUND FINANCE › Stocks › NVS

Novartis AG (NVS)

NYSE · Stock price, chart and technical analysis

US$155.21-3.92 (-2.46%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$159.13
OpenUS$157.09
Day rangeUS$154.81 – US$157.98
52-week rangeUS$123.24 – US$170.46
Market capUS$293.13B
Volume2.75M
50-day averageUS$149.57
200-day averageUS$152.67
Beta0.41
Last dividend per shareUS$4.74

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$44.0BUS$43.5BUS$46.7BUS$51.7BUS$56.7B
Net incomeUS$24.0BUS$7.0BUS$14.9BUS$11.9BUS$14.0B
EPS (diluted)10.633.177.105.877.15
Gross margin73.3%73.4%73.3%75.2%75.8%
Operating margin22.9%18.3%20.9%28.1%31.1%
Net margin54.6%16.0%31.8%23.1%24.7%
Free cash flowUS$12.5BUS$12.0BUS$11.7BUS$13.8BUS$17.6B
Total debtUS$31.0BUS$27.9BUS$26.3BUS$31.3BUS$35.4B
CashUS$12.4BUS$7.5BUS$13.4BUS$11.5BUS$11.4B

Compound annual growth: revenue 6.6% · net income -12.7% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E29.6x16.8x27.1x
EV / EBITDA15.3x11.2x16.5x
Operating margin25.5%—3.6%
Net margin17.8%—-0.0%
Debt / equity2.14—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Novartis AG

SectorHealthcare
IndustryDrug Manufacturers - General
CountryCH
CEOVasant Narasimhan
Employees75,267
IPO date1996-11-07

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with…

www.novartis.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice